Finance

Beta
Lists
VACBF:OTCMKTS
Nykode Therapeutics ASA
$0.38
0.00%
(0.00) 1D
Feb 10, 3:38:29 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VACBF...
Avg. vol.
0.00
Volume
0.00
52-wk high
$0.38
52-wk low
$0.16
Beta
0.45
Shares outstanding
326.55M
No. of employees
57
Avg. vol.
0.00
Volume
0.00
52-wk high
$0.38
52-wk low
$0.16
Beta
0.45
Shares outstanding
326.55M
No. of employees
57
News stories
From sources across the web
About Nykode Therapeutics ASA
CEOMichael Engsig
Employees57
Founded2006
Headquarters-
SectorBiotechnology
Websitenykode.com
Previous reportsAll values in NOK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
198.00K
118.00K
-
240.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.93M
3.06M
4.16M
2.87M
Operating expense
6.88M
6.40M
8.09M
6.78M
Total operating expenses
6.88M
6.40M
8.09M
6.78M
Operating income
-6.68M
-6.28M
-8.09M
-6.54M
Other non operating income
-
-
-
-
EBT including unusual items
-1.18M
-4.98M
-8.04M
-4.11M
EBT excluding unusual items
-1.18M
-4.98M
-8.04M
-4.11M
Income tax expense
-2.04M
-1.32M
-50.00K
7.00K
Effective tax rate
172.80%
26.45%
0.62%
-0.17%
Other operating expenses
3.43M
2.83M
3.42M
3.28M
Net income
859.00K
-3.66M
-8.00M
-4.11M
Net profit margin
433.84%
-3,101.69%
-
-1,713.75%
Earnings per share
-
-
-
-
Interest and investment income
1.08M
713.00K
609.00K
518.00K
Interest expense
-33.00K
-30.00K
-28.00K
-23.00K
Net interest expenses
1.05M
683.00K
581.00K
495.00K
Depreciation and amortization charges
510.00K
507.00K
504.00K
624.00K
EBITDA
-6.49M
-6.10M
-7.91M
-6.36M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer